Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Pituitary ACTH Hypersecretion × Cabergoline × NET × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 3 NET 1 Genitourinary 1 Dermatologic 1

Conditions

Prostatic Neoplasms 1 Pituitary Neoplasms 1 Pituitary ACTH Hypersecretion 1 Neuroendocrine Tumors 1 Neoplasms 1 Melanoma 1 Dumping Syndrome 1 Acromegaly 1

Interventions

pasireotide 1 Cabergoline 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01794793 2024-10-01

Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in Novartis-sponsored Studies

RECORDATI GROUP

Phase 4 Completed

337 enrolled 8 charts

DermatologicEndocrineGenitourinaryNET

Acromegaly, Dumping Syndrome, Melanoma, Neoplasms, Pituitary Neoplasms, Prostatic Neoplasms, Neuroendocrine Tumors, Pituitary ACTH Hypersecretion

Data powered by HemOnc (CC BY 4.0) Colophon ⚡